


Figure S1


Expression of Gsk3 α & Gsk3 β in U87 gliomas were evaluated, knocking down of Gsk3 α (10nM), Gsk3 β (10nM), with its specific si RNA and plasmid based over-expressing GSK3 β in two different doses 1 μ g & 2 μ g. We checked the mRNA level of Gsk3 α & Gsk3 β by real time PCR (n=3, Mean \pm SE). We also checked the mRNA expression of Gsk3 α after knocking down hnRNPA1 with its specific si RNA, compared with CNT si RNA. Housekeeping gene GAPDH expression was taken for normalization. Statistical analysis was performed considered to be significant if p value <0.05 (*), <0.01(**), and <0.001(***)).



U87

Figure S2


Expression of different proteins like phosphoERK, hnRNPA1 & c-Myc in MCF7 (Breast cancer cells) were examined in knocked down Gsk3 α (10nM), Gsk3 β (10nM), using si RNA approach. After 72hrs of transfection protein lysates were made in cell lysis buffer: 10 mM Tris-HCl (pH 7.4), 1% Triton X-100, 1 mM EDTA, protease inhibitors (Santa cruz Biotech, Inc.), phosphatase inhibitors (Abcam). SDS PAGE was run followed with western blotting to check the expression.



MCF7

Figure S3

U87 cells were grown in DMEM media, transfected with Gsk3 α (10nM) & Gsk3 β (10nM) siRNA compared with control siRNA. After 72hrs of transfection cells were treated with cycloheximide (CHX) (100 μ g/ml). Pictures were taken at different time points (0hr, 2hrs & 4hrs)



U87

Table S1: A) Gene specific PCR primers used to study alternative splicing:

S.N.	Gene Name	Forward primer (5'-3')	Reverse primer (5'-3')	Annealing (°C)
1	BIN 1	5'CCTCCAGATGGCTCCCC TGC3'	5'CCCGGGGGCAGGTCCAAGC G3'	65.7
2	MST1R (RON)	5'TGTGAGAGGCAGCTTCC AGCAG3'	5'CTAGCTGCTTCCTCCGCCAC 3'	67.3
3	Mcl-1	5'GGACACAAAGCCAATG GGCAGGT3'	5'GCAAAGCCAGCAGCACAT TCCTGA3'	58.0
4	PKM	5'GAGAATTCATGTCGAA GCCCCATAGTG3'	5'GAGTCGACTCACGGCACAG GAACAAC3'	59.0
5	GAPDH	5'ATCAAGAAGGTGGTGA AGCAG3'	5'CTTACTCCTTGGAGGCCATG T3'	62.0

B) Gene specific qRT PCR primers:

S.N.	GeneName	Forward primer (5'-3')	Reverse primer (5'-3')
1	c-Myc	5'AATGAAAAGGCCCCCGTAGTTA TCC3'	5'GTCGTTTCCGCAACAAGTCCTC TTC3'
2	Bcl-xL	5'GATCCCATGGCAGCAGTAAAG CAAG3'	5'CCCATCCCGGAAGAGTTCATT CACT3'
3	Survivin	5'TTGCTCCTGCACCCAGAGC3'	5'AGGCTCAGCGTAAGGCAGCC3'
4	Cyclin B1	5' TTGGTGTCACTGCCATGTTT 3'	5' CCGACCCAGACCAAAGTTTA 3'
5	Cyclin D1	5' TGAACTACCTGGACCGCTTC 3'	5' CCACTTGAGCTTGTTACCA 3'
6	Cyclin E1	5' TGGATGTTGACTGCCTTGAA 3'	5' TCCCCGTCTCCCTTATAACC 3'
7	Cyclin E2	5' GGAATTGTTGGCCACCTGTA 3'	5' CCCAGCTTAAATCAGGCAAA 3'
8	Gsk3 α	5' TGGCTTACACGGACATCAAA 3'	5' TCTCGCCACTGGAGTAGAAAA 3'
9	Gsk3 β	5'GGTCTATCTTAATCTGGTGCTGG 3'	5'TGGATATAGGCTAAACTTCGG AAC3'
10	GAPDH	5'ATCAAGAAGGTGGTGAAGCAG3'	5'CTTACTCCTTGGAGGCCATGT3'